Protalix BioTherapeutics features a specialized clinical and preclinical drug development pipeline anchored by its proprietary ProCellEx plant cell-based protein expression platform. Its primary clinical assets include PRX-115, a recombinant PEGylated uricase currently advancing through phase clinical evaluation for the treatment of uncontrolled gout, and PRX-119, a long-acting DNase candidate designed for respiratory conditions. Additionally, the company continuously advances early-stage discovery initiatives targeting rare renal indications and complex metabolic enzyme deficiencies.